CancerProfiler™ oncology test
An innovative whole-exome sequencing test designed for comprehensive tumour genomic profiling. It analyses thousands of gene mutations to support personalised treatment and the development of an individualised disease monitoring plan.
More precise cancer treatment starts with analysing the tumour genome
Every patient’s tumour is unique – its genetic characteristics determine treatment response, disease course, and prognosis. Conventional tests often do not reveal all clinically important tumour biomarkers.
CancerProfiler™ analyses the entire tumour exome and helps identify specific mutations that enable an individualised treatment plan and preparation for minimal residual disease monitoring in the future.
What does CancerProfiler™ analyse?
CancerProfiler™ is a whole-exome sequencing (WES) test for in-depth tumour genetic analysis that supports personalised treatment decisions. It covers thousands of genes and identifies key biomarkers that influence therapy selection and disease course.
Exome-wide sequencing: analysis of >19,000 genes
118 oncology-relevant genes, including HRR and gene fusions
Accurate differentiation of somatic mutations, inherited variants, and CHIP
Assessment of tumour mutational burden (TMB) and microsatellite instability (MSI)
Tumour vs. normal tissue (PBMC) comparison for more accurate profiling
A preparatory step for minimal residual disease monitoring with the CancerDetect™ test
Personalised treatment: when decisions are guided by tumour genetics
CancerProfiler™ enables clinicians to understand the tumour’s genetic architecture and tailor targeted therapy to the individual case. A comprehensive report supports treatment decisions, helps evaluate the likelihood of response, and supports planning for disease monitoring.
Individualised treatment plan
Exome-level analysis reveals all key tumour genetic changes that may affect treatment effectiveness.
Clear biomarkers for therapy selection
Identification of TMB, MSI, HRR, and other targets supports the use of targeted therapies and immunotherapy when genetically justified.
Distinguishing somatic and inherited mutations
Using a normal tissue control sample helps clearly separate tumour-specific changes from inherited variants or CHIP-related mutations.
Preparing for disease monitoring
CancerProfiler™ results form the basis for the CancerDetect™ test, designed to assess minimal residual disease and monitor relapse risk.
When and for whom is the test recommended?
For patients with advanced solid tumours
Helps define an individual tumour genomic profile and guide targeted therapy selection.
When eligibility for immunotherapy or targeted drugs needs evaluation
CancerProfiler™ identifies key biomarkers – TMB, MSI, HRR, and others – that support treatment decisions.
For patients planning post-treatment monitoring
Provides the foundation for the CancerDetect™ test to monitor signs of minimal residual disease.
When limited genetic testing is not sufficient
Suitable when broader genetic information is needed in a single test.
CancerProfiler™ reliability: accuracy and quality metrics
CancerProfiler™ uses advanced whole-exome sequencing (WES) to ensure broad gene coverage and high analytical accuracy. Using tumour and normal tissue samples enables precise differentiation of somatic mutations from inherited or CHIP-related changes.
Exome-wide analysis (>19,000 genes)
118 oncology-related genes, including HRR and gene fusions
Tumour genomic profiling for targeted treatment
Take the CancerProfiler™ test and receive individualised insights to support selection of the most effective treatment strategy.
For Specialists
All key information in one place – from panel content to accuracy and clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
CancerProfiler™ uses whole-exome sequencing (WES) to analyse more than 19,000 genes. This breadth provides comprehensive tumour profiling required for therapeutic decision-making and biomarker identification.
Two samples are required: tumour tissue and normal tissue (PBMC).
- Tumour: formalin-fixed, paraffin-embedded (FFPE) 10 µm sections (≥10) and one H&E-stained section with marked tumour boundaries; tumour content >30%.
- Normal tissue (recommended): peripheral blood mononuclear cells (PBMC) from 10 ml venous blood.
CancerProfiler™ includes:
- 118 clinically significant genes (including 15 HRR genes and 10 gene fusions)
- Assessment of TMB and MSI
- Identification of therapeutic targets (for immunotherapy, PARP inhibitors, etc.)
Using the PBMC control sample allows separation of somatic mutations from inherited genetic variants and clonal hematopoiesis (CHIP) – particularly important in older patients.
CancerProfiler™ results are used to create an individualised set of CancerDetect™ (ctDNA) markers, enabling post-treatment/post-surgery monitoring of Minimal Residual Disease (MRD) from the patient’s blood.
CancerProfiler™ provides comprehensive tumour genome assessment and identifies clinically relevant mutations and biomarkers (e.g., EGFR, ALK, BRAF, HER2, BRCA1/2, MSI, TMB). The report includes guideline-aligned (NCCN/ESMO) targeted therapy and immunotherapy options and highlights clinical trials that may match the patient’s profile.
